DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)

Q: What does CUSIP 25253X207 represent in this 13F holders report?

CUSIP 25253X207 is the security identifier for DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value used to aggregate holder disclosures.

Q: How many institutions held DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in Q4 2023?

37 institutional investors reported DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value for Q4 2023. Use the holders table for investor-level position and value details.

CUSIP: 25253X207

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Voting Common Shares, no par value
Shares outstanding: 52,272,727
Total 13F shares: 3,840,738
Share change: -243,610
Total reported value: $10,907,609
Put/Call ratio: 78%
Price per share: $2.84
Number of holders: 37
Value change: -$629,214
Number of buys: 16
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 25253X207?
CUSIP 25253X207 identifies DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 25253X207:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Leon G. Cooperman	13F	Individual	1.7%	875,993	$2,260,062	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	1.5%	788,789	$2,035,075	—	30 Sep 2023	13F
Altium Capital Management LLC	13F	Company	0.95%	496,000	$1,279,680	—	30 Sep 2023	13F
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE	13F	Company	0.9%	470,000	$1,212,600	—	30 Sep 2023	13F
Bleichroeder LP	13F	Company	0.43%	222,317	$573,578	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.42%	218,778	$564,597	—	30 Sep 2023	13F
Informed Momentum Co LLC	13F	Company	0.41%	212,512	$548,281	—	30 Sep 2023	13F
JACOB ASSET MANAGEMENT OF NEW YORK LLC	13F	Company	0.32%	168,730	$435,323	—	30 Sep 2023	13F
FIRST MANHATTAN CO. LLC.	13F	Company	0.22%	114,744	$296,039	—	30 Sep 2023	13F
Aristides Capital LLC	13F	Company	0.2%	106,333	$274,339	—	30 Sep 2023	13F
BlackRock Finance, Inc.	13F	Company	0.19%	101,725	$262,451	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.18%	93,800	$242,004	—	30 Sep 2023	13F
NORTHERN TRUST CORP	13F	Company	0.17%	89,700	$231,426	—	30 Sep 2023	13F
Amy L. Burroughs	3/4/5	Director	— class O/S missing	73,288	$205,206	—	03 Jan 2023	3/4/5
STATE STREET CORP	13F	Company	0.13%	66,629	$171,903	—	30 Sep 2023	13F
Harry W. Alcorn Jr.	3/4/5	SVP, Clinical Operations	— class O/S missing	43,981	$123,147	—	15 Sep 2021	3/4/5
CATALYST FINANCIAL PARTNERS LLC	13F	Company	0.07%	36,267	$93,569	—	30 Sep 2023	13F
Bank of New York Mellon Corp	13F	Company	0.07%	34,617	$89,311	—	30 Sep 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.05%	28,672	$73,974	—	30 Sep 2023	13F
MARSHALL WACE, LLP	13F	Company	0.05%	26,745	$69,003	—	30 Sep 2023	13F
Stonebridge Capital Advisors LLC	13F	Company	0.04%	20,000	$51,600	—	30 Sep 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.03%	16,959	$43,755	—	30 Sep 2023	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	15,868	$40,939	—	30 Sep 2023	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.03%	14,000	$36,120	—	30 Sep 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.03%	13,251	$34,188	—	30 Sep 2023	13F
MassMutual Private Wealth & Trust, FSB	13F	Company	0.01%	4,824	$12,446	—	30 Sep 2023	13F
US BANCORP \DE\	13F	Company	0.01%	4,335	$11,184	—	30 Sep 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	3,761	$9,704	—	30 Sep 2023	13F
TD Waterhouse Canada Inc.	13F	Company	0%	1,570	$4,810	—	30 Sep 2023	13F
Legend Financial Advisors, Inc.	13F	Company	0%	1,000	$2,580	—	30 Sep 2023	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	1,000	$2,580	—	30 Sep 2023	13F
SIMPLEX TRADING, LLC	13F	Company	0%	1,020	$2,000	—	30 Sep 2023	13F
ROYAL BANK OF CANADA	13F	Company	0%	805	$2,000	—	30 Sep 2023	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	0%	230	$593	—	30 Sep 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	163	$421	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0%	84	$217	—	30 Sep 2023	13F
JPMORGAN CHASE & CO	13F	Company	0%	25	$65	—	30 Sep 2023	13F
TORONTO DOMINION BANK	13F	Company	0%	24	$62	—	30 Sep 2023	13F
Kirsten L. Gruis	3/4/5	Chief Medical Officer	— class O/S missing	67,000	—	—	01 Jun 2023	3/4/5
Julie VanOrsdel Daves	3/4/5	SVP Clinical Development Oper.	— class O/S missing	54,000	—	—	01 Jun 2023	3/4/5
Sydney A. Gilman	3/4/5	VP, Regulatory Affairs	— class O/S missing	25,000	—	—	28 Jul 2021	3/4/5

Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q4 2023

As of 31 Dec 2023, DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,840,738 shares. The largest 10 holders included COOPERMAN LEON G, VANGUARD GROUP INC, PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE, Altium Capital Management LP, Bleichroeder LP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, MORGAN STANLEY, FIRST MANHATTAN CO. LLC., and Aristides Capital LLC. This page lists 37 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.